logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5183.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5183.produseast1
Showing 1 - 4 of 4 Items
Showing 1 - 4 of 4 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

A four-year nationwide molecular epidemiological study in Estonia: risk factors for tuberculosis transmission

Toit K, Altraja A, Acosta CD, Viiklepp P, Kremer K,  et al.
2014-10-21 • Public Health Action
2014-10-21 • Public Health Action
SETTING
Estonia has a high proportion of multidrug-resistant tuberculosis (MDR-TB). It is important to link molecular and epidemiological data to understand TB transmission patterns....
Journal Article
|
Research

Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients

Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bayona J,  et al.
2012-08-28 • PLOS Medicine
2012-08-28 • PLOS Medicine
Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has generally poor outcomes. We undertook an individual patient data meta-analysis to assess the ...
Journal Article
|
Research

Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis

Cox V, Brigden G, Crespo RH, Lessem E, Lynch S,  et al.
2018-04-01 • International Journal of Tuberculosis and Lung Disease
2018-04-01 • International Journal of Tuberculosis and Lung Disease
SETTING
The World Health Organization recommended two new drugs, bedaquiline (BDQ) and delamanid (DLM), for the treatment of multidrug-resistant tuberculosis (MDR-TB) in 2013 and 201...
Journal Article
|
Research

Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis [Review article]

Toczek A, Cox HS, du Cros PAK, Cooke GS, Ford NP
2012-12-04 • International Journal of Tuberculosis and Lung Disease
2012-12-04 • International Journal of Tuberculosis and Lung Disease
BACKGROUND: Scaling up treatment for multidrug-resistant tuberculosis is a global health priority. However, current treatment regimens are long and associated with side effects, and defa...